000261839 001__ 261839
000261839 005__ 20190619220103.0
000261839 022__ $$a2162-402X
000261839 02470 $$a000443907300023$$2isi
000261839 0247_ $$a10.1080/2162402X.2018.1462878$$2doi
000261839 037__ $$aARTICLE
000261839 245__ $$aLymphatic vessel density is associated with CD8(+) T cell infiltration and immunosuppressive factors in human melanoma
000261839 260__ $$c2018$$aPhiladelphia$$bTAYLOR & FRANCIS INC
000261839 269__ $$a2018-01-01
000261839 336__ $$aJournal Articles
000261839 520__ $$aIncreased density of tumor-associated lymphatic vessels correlates with poor patient survival in melanoma and other cancers, yet lymphatic drainage is essential for initiating an immune response. Here we asked whether and how lymphatic vessel density (LVD) correlates with immune cell infiltration in primary tumors and lymph nodes (LNs) from patients with cutaneous melanoma. Using immunohistochemistry and quantitative image analysis, we found significant positive correlations between LVD and CD8(+) T cell infiltration as well as expression of the immunosuppressive molecules inducible nitric oxide synthase (iNOS) and 2,3-dioxygenase (IDO). Interestingly, similar associations were seen in tumor-free LNs adjacent to metastatic ones, indicating loco-regional effects of tumors. Our data suggest that lymphatic vessels play multiple roles at tumor sites and LNs, promoting both T cell infiltration and adaptive immunosuppressive mechanisms. Lymph vessel associated T cell infiltration may increase immunotherapy success rates provided that the treatment overcomes adaptive immune resistance.
000261839 650__ $$aOncology
000261839 650__ $$aImmunology
000261839 650__ $$aOncology
000261839 650__ $$aImmunology
000261839 6531_ $$aimmunotherapy
000261839 6531_ $$alymphatics
000261839 6531_ $$atumor immunology
000261839 6531_ $$at cell inhibition
000261839 6531_ $$at cell promotion
000261839 6531_ $$agrowth factor-c
000261839 6531_ $$aprimary cutaneous melanoma
000261839 6531_ $$apromotes tumor-metastasis
000261839 6531_ $$amalignant-melanoma
000261839 6531_ $$aendothelial-cells
000261839 6531_ $$aadoptive immunotherapy
000261839 6531_ $$acancer-immunotherapy
000261839 6531_ $$amicrovessel density
000261839 6531_ $$ainterstitial flow
000261839 6531_ $$anode metastasis
000261839 700__ $$aBordry, Natacha
000261839 700__ $$aBroggi, Maria A. S.
000261839 700__ $$ade Jonge, Kaat
000261839 700__ $$aSchaeuble, Karin
000261839 700__ $$aGannon, Philippe O.
000261839 700__ $$aFoukas, Periklis G.
000261839 700__ $$aDanenberg, Esther
000261839 700__ $$aRomano, Emanuela
000261839 700__ $$aBaumgaertner, Petra
000261839 700__ $$g214316$$0250016$$aFankhauser, Manuel
000261839 700__ $$aWald, Noemie
000261839 700__ $$aCagnon, Laurene
000261839 700__ $$aAbed-Maillard, Samia
000261839 700__ $$aMaby-El Hajjami, Helene
000261839 700__ $$g292518$$0253951$$aMurray, Timothy
000261839 700__ $$aIoannidou, Kalliopi
000261839 700__ $$aLetovanec, Igor
000261839 700__ $$aYan, Pu
000261839 700__ $$aMichielin, Olivier
000261839 700__ $$aMatter, Maurice
000261839 700__ $$aSwartz, Melody A.$$0242992$$g160091
000261839 700__ $$aSpeiser, Daniel E.
000261839 773__ $$qe1462878$$k8$$j7$$tOncoimmunology
000261839 8560_ $$fpierre.devaud@epfl.ch
000261839 909C0 $$0252115$$meliane.blumer@epfl.ch$$zBlumer, Eliane$$xU11747$$pLLCB$$yApproved
000261839 909CO $$ooai:infoscience.epfl.ch:261839$$particle
000261839 961__ $$afantin.reichler@epfl.ch
000261839 973__ $$aEPFL$$sPUBLISHED$$rREVIEWED
000261839 980__ $$aARTICLE
000261839 980__ $$aWoS
000261839 981__ $$aoverwrite